Accelerating Clinical Research with Master Protocols:
Challenges and Benefits to Complex Trial Designs

Beth Chamblin has 25 years of experience in pharmaceutical/biopharmaceutical development, including over 15 years in global clinical project management and four years in oncology project management. At IQVIA Biotech, she specializes in strategic oversight of late-phase global clinical programs, supporting emerging biotech companies. Beth has managed global Phase I-III studies across multiple regions and has expertise in novel trial designs. She also leads a team of 10 project managers/directors, providing mentoring and support. Her broad experience allows her to align each study with a company’s long-term goals, ensuring project success.

Kelley Coalier is a strategy consultant with 14 years of experience in the life sciences. She collaborates with biopharma, academia, government and nonprofits to foster innovative approaches and leverage cutting-edge technologies. Kelley has played a pivotal role in establishing public-private partnerships and supports streamlined decision-making and process efficiency in clinical development. Her diverse background enables her to optimize efficiencies and assess readiness for new capabilities, ensuring clients’ missions and visions are realized.

Brad Smith is the Vice President of Therapeutic Strategy, specializing in translational medicine. He is a recognized leader in biomarkers and companion diagnostics in clinical research, with expertise in technical, scientific, regulatory, legal and business aspects. Previously, Brad led Corporate Development at Cell Signaling Technology and managed the translational medicine lab. His scientific background includes research at Stanford University and UCSF, focusing on disease mechanisms. Brad holds a Doctoral degree from Stanford University and Master’s and Bachelor’s degrees from UC Santa Cruz.